Archive for the ‘BioTechnology – Venture Creation’ Category

Life Science and Digital Health Investments – 2020 World Medical Innovation Forum – COVID-19, AI – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Posted in AI-assisted Cardiac MRI, Artificial intelligence applications for cardiology, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Artificial Intelligence in Psychiatry, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Coronavirus Gene Expression, COVID-19, Deep Learning in Pathology, Innovations, Population Health Management, Genetics & Pharmaceutical, R&D Expenditure, SARS-CoV-2, Serology tests for coronavirus antibodies, Virus Infective Acute Respiratory Syndrome: SARS-CoV on May 12, 2020| Leave a Comment »

2020 World Medical Innovation Forum – COVID-19, AI – Life Science and Digital Health Investments, MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Life science and digital health investments have continued at a strong pace during the COVID-19 crisis. Senior investment leaders discuss what to expect. Will:

social distancing affect deal making?
key asset categories remain strong – venture, private equity, public offerings, acquisitions?
valuations hold up in some categories while others fall?

Moderator: Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham

Jan Garfinkle, Founder & Manager Partner, Arboretum Ventures, Chair NVCA

Phillip Gross, Managing Director, Adage Capital Management

Christopher Viehbacher, Managing Partner, Gurnet Point Capital

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum

Dear World Forum Attendee,

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators. As promised, we wanted to also share visual Forum session summaries. You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

Read Full Post »

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Reporter: Stephen J. Williams, PhD

New Drugs on the Horizon: Part 3
Introduction

Andrew J. Phillips, C4 Therapeutics

symposium brought by AACR CICR and had about 30 proposals for talks and chose three talks
unfortunately the networking event is not possible but hope to see you soon in good health

ABBV-184: A novel survivin specific T cell receptor/CD3 bispecific therapeutic that targets both solid tumor and hematological malignancies

Edward B Reilly
AbbVie Inc. @abbvie

T-cell receptors (TCR) can recognize the intracellular targets whereas antibodies only recognize the 25% of potential extracellular targets
survivin is expressed in multiple cancers and correlates with poor survival and prognosis
CD3 bispecific TCR to survivn (Ab to CD3 on T- cells and TCR to survivin on cancer cells presented in MHC Class A3)
ABBV184 effective in vivo in lung cancer models as single agent;
in humanized mouse tumor models CD3/survivin bispecific can recruit T cells into solid tumors; multiple immune cells CD4 and CD8 positive T cells were found to infiltrate into tumor
therapeutic window as measured by cytokine release assays in tumor vs. normal cells very wide (>25 fold)
ABBV184 does not bind platelets and has good in vivo safety profile
First- in human dose determination trial: used in vitro cancer cell assays to determine 1st human dose
looking at AML and lung cancer indications
phase 1 trial is underway for safety and efficacy and determine phase 2 dose
survivin has very few mutations so they are not worried about a changing epitope of their target TCR peptide of choice

The discovery of TNO155: A first in class SHP2 inhibitor

Matthew J. LaMarche
Novartis @Novartis

SHP2 is an intracellular phosphatase that is upstream of MEK ERK pathway; has an SH2 domain and PTP domain
knockdown of SHP2 inhibits tumor growth and colony formation in soft agar
55 TKIs there are very little phosphatase inhibitors; difficult to target the active catalytic site; inhibitors can be oxidized at the active site; so they tried to target the two domains and developed an allosteric inhibitor at binding site where three domains come together and stabilize it
they produced a number of chemical scaffolds that would bind and stabilize this allosteric site
block the redox reaction by blocking the cysteine in the binding site
lead compound had phototoxicity; used SAR analysis to improve affinity and reduce phototox effects
was very difficult to balance efficacy, binding properties, and tox by adjusting stuctures
TNO155 is their lead into trials
SHP2 expressed in T cells and they find good combo with I/O with uptick of CD8 cells
TNO155 is very selective no SHP1 inhibition; SHP2 can autoinhibit itself when three domains come together and stabilize; no cross reactivity with other phosphatases
they screened 1.5 million compounds and got low hit rate so that is why they needed to chemically engineer and improve on the classes they found as near hits

Closing Remarks

Xiaojing Wang
Genentech, Inc. @genentech

Follow on Twitter at:

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Posted in BioTechnology - Venture Creation, IP Development by LPBI Group Team, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on February 28, 2020| Leave a Comment »

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Author: Aviva Lev-Ari, PhD, RN

https://feinternational.com/blog/how-do-you-value-an-online-business/

How to Value a Website or Internet Business in 2020

From: Thomas Smale <acquisitions@feinternational.com>

Reply-To: <acquisitions@feinternational.com>

Date: Thursday, February 27, 2020 at 4:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Your Guide to Buying an Online Business

Hi Aviva

Thanks for your interest in our free Guide to Buying an Online Business. Please click below to download.

Guide-to-Buying-an-Online-Business-vLQ

Guide-to-Buying-an-Online-Business-vHQ

We will be in touch in a few days to see if you have any questions!

Regards,

Thomas Smale
Founder

FE International, Inc.

www.feinternational.com

FE International Framework

Alternative Metrics for Valuing Websites Or Internet Business

Discounted Cashflow Analysis
Precedent Transactions
Earnings-Multiple
Traffic Valuation
A Multiple-Based Approach to Valuing a Website or Internet Business

Defining Profitability

Factors That Influence The Multiple: Financials, Traffic, Operations, niche, Customer base

Valuation Multiples In Practice

Image source:

https://feinternational.com/blog/how-do-you-value-an-online-business/

Consider the Current Business Model

How to Value a SaaS Business

How to Value an E-Commerce Business

How to Value an App

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

On 2/27/2020 5:30AM – Aviva Wrote:

This is an excellent article.

It is very applicable for

1. Travel Websites

2. eCommerce transaction sites

3. Content: chiefly NEWS

CLAIMER:

Our PharmaceuticalIntellugence.com

A. Is an Internet based Business of Digital Content

B. Unlike 1,2,3 –

B.1 EVERY CURATION in the Journal

has content with INTRINSIC value in the form of IP belonging to the Curator’s Expertise

B.2 ALL 16 Volumes in the BioMed e-Series represent an ORIGINAL electronic Table of Contents eTOCs designed by a very unique Editor(s).

B.2.1 The evolution of the eTOCs takes many iterations among the editors AND only the Editor-in-Chief after requests for substantial alterations, usually ADD new content, declares “This is the final eTOCs for Series X, Volume Y.

(These alterations AUGMENT the IP embedded in the eTOCs design)

Example:

Genomics Volume 2: there were three iterations of eTOCs between Prof. Feldman and Aviva, first dated 2016.

In 2019,

• Aviva created single handedly the FINAL version of eTOCs and

• commissioned ALL scientists to populated Parts 7 and 8 with new content not in existence in the Journal.

• made Part 3: AI in Medicine

• made Part 4: Single Cell Sequencing

• obtained from Part 5: Evolution & Genomics from Prof. Feldman as an original curations WRITTEN for this Volume

THAT IS INTRINSIC VALUE DERIVED FROM EXPERTISE and it defines the QUALITY of this book, which is not measured by traffic. Advertisement of the book could drive page downloads and book sales. It can be done ANY TIME because each article in the book is updated in perpetuity !! A feature of our BioMed e-Series.

Does the DCF model capture the value of NON-perishable content in our Jornal and Books – no it does not

It will be valued at PREMIUM an acquirer who is sensitive to content obsolescence !!!!!

B.2.2 Page downloading will be updated for 4/19/2020

C. eProceedings are generated by Experts and the TWEET Collections carry the favorable Tweet Analytics that we presented:

• HIGH engagement,

• HIGHEST ratio tweet/likes in the Industry

• Ranked 2nd, 3rd, 4th in TOP 10 Influencers at #1 Conference in AI in Medicine in the World, 4/2019

HOW THUS VALUATION article calling for 2 to 4.5 multiplier is to capture LPBI’s

1. ECONOMIC intrinsic value on non perishable content

2. Top Expertise

3. electronic Reputation and other INTANGIBLE ASSETS as VALUE DRIVERS

FE International’s model has only LIMITED applicability to valuation of LPBI Portfolio of Intellectual Property.

Our venture shares several industries, we have identified 12 economic segments where an acquirer can be identified. The content created using the methodology of curation of scientific findings with clinical interpretation by experts was developed in house to mitigate the information explosion in the Life Sciences and the information obsolescence. The content lands its attribution to electronic Scientific Publishing and to Pharmaceutical Media. Please review the business functions that this content could contribute to by the value drivers in each economic segment https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Introduction to Three Intellectual Property Asset Classes of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

http://pharmaceuticalintelligence.com

LPBI Scientific Journal: 1.7Million eReaders, 5700 scientific articles [Pharmaceutics, Life Sciences, Medicine], 690 categories of research, 10,154Tags

https://lnkd.in/eEw5q7N

BioMed e-Series: 16 Volumes in Medicine and Life Sciences

https://lnkd.in/ekWGNqA

e-Proceedings: Corpus of +70 Biotech & Medical Conferences, events covered in real time by a methodology developed in house yielding the e-Proceeding with one click at the end of the Conference.

https://lnkd.in/dc2qGAK

OTHER ASSETS

Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations

Asset Class V is a Gallery of ~5000 images used in the articles and books

Asset Class VI is the Team of Experts.

Asset Class VII: Royalties on BioMed e-Series

Read Full Post »

2020 State of Possible Conference, MassBio’s Annual Meeting, March 25-26, 2020, Sonesta Hotel, Cambridge, MA

Posted in BioTechnology - Venture Creation, Conference Coverage with Social Media on February 21, 2020| Leave a Comment »

2020 State of Possible Conference, MassBio’s Annual Meeting, March 25-26, 2020, Sonesta Hotel, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in REAL TIME

for

http://pharmaceuticalintelligence.com

by @pharma_BI and by @AVIVA1950

https://massbio.microsoftcrmportals.com/event/?event=2020_State_of_Possible_Conference378018264

Session Title	Start Time	End Time
Welcome	3/25/2020 10:00 AM	3/25/2020 10:30 AM
Opening Keynote Billy Starr, Founder & Executive Director, Pan Mass Challenge, “Closer by the Mile: How One Man Shaped the Athletic Fundraising Industry with the Power of a Bike”	3/25/2020 10:30 AM	3/25/2020 11:15 AM
Shifting the Drug Industry’s Public Narrative Through Stories of Success Doctors have among the highest favorability ratings of any profession. Life sciences employees are your next-door neighbors who are developing the next breakthrough therapy. Can their first-hand stories and experiences shift and shape the public debate about prescription drug prices that has so far only painted a picture of corporate greed over miracle cures? At its heart, the public debate lacks any understanding about the true value the biopharma industry brings to patients and the healthcare system. This panel will address the critical need to reshape the public debate about drugs, innovation, and the industry and how first-hand experience of patients, employees, and physicians could be a critical piece of reframing the debate.	3/25/2020 11:15 AM	3/25/2020 12:00 PM
Lunch	3/25/2020 12:00 PM	3/25/2020 1:00 PM
Possible Talk: Dr. Steven Arnold, Interdisciplinary Brain Center, MGH	3/25/2020 1:00 PM	3/25/2020 1:15 PM
Lessons from Abroad: What, When, and How to Ensure Access and Reimbursement As more next-generation and highly personalized therapies reach the market, often approved by regulators on accelerated approval pathways, payers in the U.S. are becoming more selective and conservative with their coverage and reimbursement decisions. Yet, this environment is not new outside of the U.S. where there is prevalent usage of health technology assessments and comparative effectiveness calculations by government run payers to make access and pricing determinations. This panel will discuss their experience gaining coverage and pricing determinations in ex-U.S. markets and how lessons learned can help any company better develop a case for value for their product as they seek approvals and coverage in the U.S. and abroad.	3/25/2020 1:15 PM	3/25/2020 2:00 PM
Possible Talk: Morgan Stanley	3/25/2020 2:00 PM	3/25/2020 2:15 PM
Building a Digital Health Community in Massachusetts The biopharma industry is increasingly utilizing digital technologies and digital health tools that promise to modernize drug discovery and development, along with patient care and measurement of patient outcomes. There has been continued focus on supporting this convergence in Massachusetts, both within the leading academic institutions and government, but there’s still much more than can be done to build a sustainable community here. This panel will draw insights from other clusters on how to support better connectivity and collaboration between digital health and the life sciences.	3/25/2020 2:15 PM	3/25/2020 3:00 PM
Possible Talk: “ONE.” Lisa Tremayne, President, Advocate, Survivor. The Bloom Foundation	3/25/2020 3:00 PM	3/25/2020 3:15 PM
Networking Break	3/25/2020 3:15 PM	3/25/2020 3:30 PM
From Seed to Series A: Creative Ways to Fund Your Startup The platform-based, venture-created, $100M+ Series A startup is now a fixture in Massachusetts biotech. However, most first-time founders come straight from academia and struggle to secure funding to demonstrate meaningful in-vivo efficacy of their product candidate. Since therapeutics’ risk, time and scale of capital doesn’t match the needs of angel investors, who will fund the next generation of great ideas and leaders? This panel will explore alternate forms of funding along with the critical role of mentors, advisory boards, and other support systems in navigating this landscape.	3/25/2020 3:30 PM	3/25/2020 4:15 PM
The Dark Side of the Genome – What We Know About the Unknown Up to 98% of humans’ 3.2 billion base-pairs of DNA has no known function. Some is the long history of viruses and other genetic parasites we carry forward; however, there is also incredible potential to tap into this dark DNA. Future drug targets are becoming increasingly accessible through tools like gene editing and gene therapy that may open massive uncharted opportunity for the dark side of the genome.	3/25/2020 3:30 PM	3/25/2020 4:15 PM
Attracting & Engaging the Next Generation of Talent The specialized skills and deep experience required to successfully bring a new therapy to market are in short supply. Companies are finding it increasingly difficult to find the right candidates, retain them, and keep them focused and engaged across the broad arc of technical, clinical, and financial risks inherent to our industry. This panel will address how we can better align with academia to build our future workforce, how to attract diverse talent from outside traditional networks, and how to better engage and promote current workers within.	3/25/2020 4:15 PM	3/25/2020 5:00 PM
Is Aging a Disease and What Are the Implications of Treating it as Such? Along the route of better understanding the cellular and molecular underpinnings of cancer, immuno-oncology and neurological diseases, science has shed light on the mechanisms of aging. In addition to the diseases of old age, is aging itself a disease and what would it mean to treat or ‘snooze’ our biological clocks?	3/25/2020 4:15 PM	3/25/2020 5:00 PM
Resilience, Grit, Freedom to Fail and Pivot Biotech is not for the risk averse. Most successful entrepreneurs and investors have experienced multiple failures on their way to commercialization, and many have had to scrap what they were working on and start over. Beyond the statistics of scientific and clinical results missing desired endpoints, hear the personal stories of those who have lived the ups and downs of the long journey from intriguing science to patient bedside.	3/25/2020 5:00 PM	3/25/2020 5:45 PM
Realities of Precision Medicine – How Small is Too Small? The world of precision medicine has evolved dramatically over the years, with targeted treatment for specific patients dating back 2,500 years to Hippocrates. Although genetic and biomarker testing to guide treatment is possible, and in theory should improve care while lowering costs, barriers to widespread adoption remain. Hear from expert panelists as they offer competing views on the shifting paradigm, from biohackers and ultra-rare disease, to more mainstream targeting. How small is too small?	3/25/2020 5:00 PM	3/25/2020 5:45 PM
Evening Reception at Museum of Science & Presentation of The State of Possible Award	3/25/2020 6:00 PM	3/25/2020 9:00 PM
Breakfast	3/26/2020 8:45 AM	3/26/2020 9:30 AM
Possible Talk, Safi Bahcall, Author, “Loonshots”	3/26/2020 9:30 AM	3/26/2020 9:45 AM
What the Coronavirus Can Teach Us About How to Approach the Next Pandemic The Coronavirus continues to dominate headlines around the world, creating widespread panic and fast action by industry, governments, and NGOs. How do we continue this push for solutions long after the latest pandemic has subsided? Panelists will review the current state of infectious diseases and share insights on how to better prevent and treat infectious disease through new vaccines, antimicrobials, and antivirals.	3/26/2020 9:45 AM	3/26/2020 10:30 AM
Possible Talk: Dennis Grishin, Co-Founder, Nebula Genomics	3/26/2020 10:30 AM	3/26/2020 10:45 AM
Supporting Regional Growth of the Life Sciences Beyond Cambridge One of the greatest strengths of Kendall Square is the sheer density of biopharmas, research institutions, academic institutions, and proximity to the best academic medical centers in the world. Yet, the success of this mini cluster within Massachusetts is also its greatest weakness. Companies struggle to afford the real estate and employees are increasingly frustrated with their commutes and housing costs – leading more companies to move outside of Cambridge. This panel will address why this is a good thing, how to support the continued growth of the industry across Massachusetts, and what kinds of infrastructure investments must be made to ensure success.	3/26/2020 11:00 AM	3/26/2020 11:45 AM
AI and Drug Discovery: Marrying Data Science with Core Biology Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating ‘wet’ in vitro/in vivo and ‘dry’ insilico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This panel will explore the new world of digital biology as a way to model potential drug effects more accurately and quickly.	3/26/2020 11:00 AM	3/26/2020 11:45 AM
Finding a Needle in a Haystack: Asymptomatic Detection of Cancer and Other Diseases As medicine moves away from chronic management of disease toward one-time cures, early detection of pre-symptomatic cancers and other serious diseases is more important than ever. The problem? Nobody wants to pay for diagnostics and genomic testing, especially for something rare or for a disease with no current treatment options. Hear ideas on how to efficiently process and pay for testing a “haystack” of healthy patients in order to find the one “needle” to predict future disease.	3/26/2020 11:45 AM	3/26/2020 12:30 PM
Lifting the Curtain on R&D to Advance New Drug Targets Faster Science is driven by reproducible experimental evidence under peer-review toward global consensus, and it’s full of trial-and-error. There has been a push by some to make that research – successes and failures – more transparent to prevent others from making the same mistakes or going after the wrong targets. What can our innovation ecosystem do to share findings widely, challenge engrained beliefs, and follow new avenues, all while preserving a competitive advantage that academic and industry research require?	3/26/2020 11:45 AM	3/26/2020 12:30 PM
Innovative Leadership Award Presentation & Lunch MassBio’s Innovative Leadership Award honors Dr. Abbie Celniker who has contributed significantly to the growth and success of the life sciences in Massachusetts, is a leader in her communities, and a leader for employees by creating a positive work environment.	3/26/2020 12:30 PM	3/26/2020 1:30 PM
Closing Keynote, Susan Hockfield, insights on her new book and leadership	3/26/2020 1:30 PM	3/26/2020 2:30 PM
Closing Networking Dessert Reception	3/26/2020 2:30 PM	3/26/2020 3:00 PM

SPEAKERS

https://massbio.microsoftcrmportals.com/speakers/?event=2020_State_of_Possible_Conference378018264

Read Full Post »

youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on December 17, 2019| Leave a Comment »

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is pleased to invite you to youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

First Round of VC Firms Announced

Second Virtual Summit to feature over 100 VCs

Friends,

We’re pleased to announce the first round of VCs confirmed to be featured at Venture Summit Virtual Connect | Global being held on August 4^th – 6^th, 2020.

This exclusive venture summit will bring together over 1,300 VCs, corporate VCs, angel investors, industry executives, and founders of venture-backed, emerging, and early-stage companies, will feature more than 100 leading VCs, presentations by 100 cutting-edge innovators, and high-level networking opportunities.

Submit your company for the opportunity to present to leading investors: Click here

Connect with leading early stage VCs

Susan Akbarpour

Partner

Candou Ventures

Sep Alavi

Venture Partner

White Star Capital

Grant Allen

General Partner

Schneider Electric Ventures

Logan Allin

General Partner

Fin Venture Capital

Milad Alucozai

Partner

Good AI Capital

Amolak Badesha

Investor

Sand Hill Angels

Wade Bitaraf

Founder, Energy & Sustainability

Plug & Play Tech Center

Greg Bohlen

Managing Director

Union Grove Venture Partners

Christophe Bourque

General Partner

White Star Capital

Daniel Burstein

Managing Partner

Millennium Technology Value Partners

Adam Carson

Operating Partner

Point72 Ventures

Jeffrey Cherry

Co-Founder & Executive Director

Conscious Venture Lab

Elizabeth Cho-Fertikh

Cofounder & Managing Director

MEDA Angels

Andy Clapp

Managing Partner

Arctaris Capital Partners

Jay Crone

Director, Investments

TELUS Ventures

Lake Dai

Partner

LDV Partners

Angelo Del Priore

Partner

HP Tech Ventures

Jun Deng

Investment Partner

Joyance Partners

Robert Dunkle

Founder and CEO

ABES Venture Partners

Amy Dyck

Associate

Framework Venture Partners

Nick Efstratis

Managing Director

EPIC Ventures

Mark Farrell

Managing Director

Thayer Ventures

Andrew Felbinger

Investor

Urban Innovation Fund

Constance Freedman

Managing Partner

Moderne Ventures

Isabelle Freidheim

Managing Partner

Starwood VC

Stan Fung

Managing Director

FarSight Ventures

Norm Gitis

Managing Partner

Lymo Ventures

Ajay Gopal

Principal

Framework Venture Partners

Robert Hamlin

Principal

Portag3 Ventures

Florian Haupt

Partner

TruVenturo

Ben Jen

Investor

Ben Jen Holdings

Najib Khouri-Haddad

General Partner

Sway Ventures

Ryan Kole

Partner

VCapital

Elaine Kunda

Founder, Managing Director

Disruption Ventures

Eddie Lee

Principal

White Star Capital

James Lee

Director

Photon Fund Venture Capital

Jessica Li

Investor

Soma Capital

Ephraim Lindenbaum

Managing Director

Advance Ventures

Darwin Ling

Founding General Partner

Good AI Capital

Edwin Loredo

Vice President

Core Innovation Capital

Wasim Malik

Managing Partner

Iaso Ventures

Eugene Malobrodsky

Venture Partner

One Way Ventures

Eric Martineau-Fortin

Co-Founder and Managing Partner

White Star Capital

Philip Mertens

Associate

DSM Venturing

Ivan Nikkhoo

Managing Partner

Navigate Ventures

Carlos Ochoa

Managing Partner

AI8 VENTURES

Valerie Photos

Operating Partner

Iaso Ventures

Filipe Portela

Managing Partner

COREangels Atlantic

Safa Rashtchy

Managing Director

Think + Ventures

John Ricci

Managing Director

US Angels

Alex Rozenfeld

Managing Director

Climate Impact Capital

Gayatri Sarkar

Managing Partner

Hype Capital VC Fund

Brian Schuman

Investment Professional

PepsiCo Technology Ventures

Kristina Serafim

Managing Director

Verizon Ventures

Greg Shepard

Managing Partner

BOSS Capital Partners

Charles Sidman

Managing Partner

ECS Capital Partners

Sean Simpson

Director

WIND Ventures

Jean Sini

General Partner

Partech

Mark A. Solovy

Managing Director

Monroe Capital

Vivek Soni

General Partner

S Cap Cleantech Fund

Kat Utecht

Managing Partner

Core Innovation Capital

Jordan Wahbeh

Managing Partner

SV Venture Group

Henry Wong

Managing Partner

Diamond Tech Ventures

Stephanie Zepeda

Senior Associate

Arbor Ventures

We’re just getting started, more to be announced!

CALL FOR

TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators from the fintech, technology, clean-tech, life sciences/healthcare, medical devices, healthcare IT, and mobile sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners!

First Round Submission Deadline for presenting company applications is TODAY June 11^th, 2020.

To apply, your company must be privately held and ideally come from one of the following industry sectors:

Tech

Life Sciences / Healthcare

CleanTech

FinTech

EdTech

Hardware

Internet/Digital Media

IoT

Mobile

Security

Software/IT

Biotech

Diagnostics

Drug Discovery

Healthcare IT

Medical Devices

Pharma

Energy Efficiency

Energy Generation

Energy Infrastructure

Energy Storage

Transportation

Water & Wastewater

Banking

Blockchain

Insurtech

Personal Finance

Payments

Predictive Analytics

Questions about presenting? Email Preston Michaels at iwant2present (at) youngstartup .co

Seed Stage Track

If you are a seed-stage company seeking angel funding and would like to present check out our seed stage track.

If you’re seeking less than $1M (and have raised less than $300,000) this is for you.

Joe Benjamin

Founder & CEO

youngStartup Ventures

“Where Innovation Meets Capital”

Don’t hesitate to connect with me personally via LinkedIn and request to join our venture network LinkedIn group below.

August 4-6, 2020

Contact

youngstartup.com/vcglobal

info@youngstartup.co

212.202.1002

@@@@@

Save 20% with discount code LPBI-VIP

NEW DATE

May 5 – 7, 2020

UPDATED on 4/21/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group invites you to join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze Register here today to confirm your spot: http://bit.ly/2PfsbM7 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

Whether you are an investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.

Twitter

Join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register here today to confirm your spot: http://bit.ly/2PfsbM7 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

Where do #startups connect with leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register at http://bit.ly/2PfsbM7 and get 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

Facebook

Leaders in Pharmaceutical Business Intelligence (LPBI) Group invites you to join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5^th– 7^th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register here today to confirm your spot: http://bit.ly/2PfsbM7 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

@@@@

Venture Summit \ Virtual Connect

Where Innovation Meets Capital

May 5 – 7, 2020

Join early stage VCs, Corporate VCs, Angel Investors and founders of venture backed, emerging and early stage companies at Venture Summit \ Virtual Connect on May 5-7 2020.

Whether you’re a startup seeking capital and exposure, or an investor seeking new deals, Venture Summit \ Virtual Connect is one event you won’t want to miss.

A highly productive venture conference, Venture Summit \ Virtual Connect will feature:

Over 100 VCs (regional and national)
Presentations by 100 Top Innovators
One-on-One (zoom) investor + startup meetings
2 days of content including timely panel discussions and workshops
Keynote: Uri Levine, co-founder of Waze

Special Offer:

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has made special arrangement for our network to receive 20% off with discount code LPBI-VIP (Note: Rates will go up this Thursday at midnight but the discount will still apply).

Register Today & Save Click here http://bit.ly/2PfsbM7.

Over 100 Investors Confirmed:

11.2 Capital, 500 Startups, ABES Venture Partners, Activate Capital, Advance Ventures, Aligned Partners, Alliance of Angels, Alliance Ventures, Alpha Square Group, American Family Ventures, AMINO Capital, Anzu Partners, Arbor Ventures, ARIE Capital, Asset Management Ventures, Augment Ventures, Avestria Ventures, BAM Ventures, Band of Angels, Bay Angels, Bee Partners, Ben Jen Holdings, Benhamou Global Ventures, Better Ventures, Blue Bear Capital, Blue Bear Ventures, Blue Startups, BlueRun Ventures, Boehringer Ingelheim Venture Fund, Boeing HorizonX Ventures, Brand New Matter, Candou Ventures , Catapult VC, Charles River Ventures, CIG CAP, Citi Ventures, City Light Capital, Clean Energy Venture Group, Communitas Capital Partners, Core Innovation Capital, COREangels Atlantic, Costanoa Ventures, Cottonwood Technology Fund, CRCM Ventures, Crestlight Ventures, Data Collective, Deutsche Telekom Capital Partners, DHVC, DigitalDX Ventures, Disruption Ventures, Dow Ventures, DPH Ventures, DSM Venturing, DXA Investments, Dynamk Capital, E. ON , E8 Angels, ECS Capital Partners, Elevate Ventures, Energy Foundry, Energy Innovation Capital, ENGIE New Ventures, Eudemian Ventures, Evok Innovations, F-Prime Capital, Fidelity Investments, Financial Venture Studio, FinSight Ventures, Fort Ross Ventures, Foundation Capital, Framework Venture Partners, Galaxy Digital, Garage Technology Ventures, GM Ventures, Good AI Capital, Good Growth Capital, H.I.G. Growth Partners, Halogen Ventures, Harvard Business School Angels, HealthTech Capital, Henkel Ventures, HP Tech Ventures, Hype Capital VC Fund, Insight Partners, JetBlue Technology Ventures, Johnson & Johnson Innovation – JJDC, Journey Venture Partners, Joyance Partners, Juniper Networks, K5 Ventures, Kubera Venture Capital, Lam Capital, Life Science Angels, Lymo Ventures, Magnet Ventures, ManchesterStory Group, Marcy Venture Partners, McKesson Ventures, Mighty Capital, Millennium Technology Value Partners, Moderne Ventures, Morpheus Ventures, Munich Re Ventures, MVM Partners, National Science Foundation, Navigate Ventures, NEA, New Science Ventures, New York Life Ventures, NextGen Venture Partners, NextWorld Capital, Nielsen Innovate, OCA Ventures, One Way Ventures, Owl Ventures, Pangaea Ventures, Paypal Ventures, Photon Fund, Pipeline Angels, Plug & Play Tech Center, Point72 Ventures, Portag3 Ventures, Portfolia, Prelude Ventures, PROOF VC, Revel Partners, SABIC Ventures, Samsung Catalyst Fund, Sand Hill Angels, Santander InnoVentures, Saudi Angel Fund, Shasta Ventures, SignalFire, Social Impact Capital, Spike Ventures, Starwood VC, Sunrise Capital Partners, Sway Ventures, Tech Coast Angels, The Westly Group, TiE Angels, TruVenturo, UL Ventures, Union Grove Venture Partners, Unusual Ventures, US Angels, Verizon Ventures, Viridian Capital, VisionPassage, Volvo Cars Tech Fund, WAVE Equity Partners, Wharton Alumni Angels More to be announced.

More details: http://bit.ly/2PfsbM7

We look forward to seeing you there.

Leaders in Pharmaceutical Business Intelligence (LPBI) Group & youngStartup Ventures

OLD CONTENT

NEW DATE Venture Summit | West – “Where Innovation Meets Capital”, May 5 – 7, 2020,

Santa Clara Convention Center, Silicon Valley

VSW20 – Discount code, LPBI-VIP and unique event site link http://bit.ly/2PfsbM7.

Video link for most recent event http://bit.ly/2LQpONN

UPDATED on 3/25/2020

The dedicated discount code LPBI-VIP and unique event site link http://bit.ly/2PfsbM7 now entitles LPBI network to $350 off the current rates. Applicants should register as soon as possible to lock in the lowest possible rates.

We will be hosting 1on1 startup and investor meetings live at Venture Summit | West [digital edition] online in May. The summit will now be expanded for featured companies to 3 days, May 5^th – 7^th (coaching session + 2 days of content and one on one sessions) and for general attendees to 2 days.

The summit will feature over 150 venture funds as speakers/judges (many others in attendance), more than 100 Top Innovators as presenters, effective and seamless 1:1 meetings + chat, and high-level networking opportunities.

The screening committee is currently interviewing companies and will be selecting more than 100 Top Innovators to present live to the investors at the summit.

Featured Confirmed VC Speakers & Judges:

	Kira Noodleman Bee Partners

	Kira enjoys tackling problems in disruptive industries and across cultures. Her appreciation for skillful risk-taking attracted her to entrepreneurship, and ultimately to her role in venture capital. At Bee Partners, she spends the majority of her time identifying and investing in Founders and startups servicing enterprises and enabling new marketplaces. She dedicate the remainder of […] Read more
	Li Sun Foundation Capital

	Li Sun comes from a global background spanning four countries with diverse experiences across engineering, science, technology, and entrepreneurship. She holds a B.Eng in EE and business (1st class honors) from NTU in Singapore, an M.Eng in Materials Science from MIT, and a PhD in Applied Physics from Harvard. During her PhD, she cofounded and […] Read more
	Bill Reichert Garage Technology Ventures

	Bill Reichert is co-founder and Managing Director of Garage Technology Ventures, a seed and early stage venture capital firm based in Silicon Valley. He is also a Partner at Pegasus Tech Ventures, a global venture capital firm with offices in Silicon Valley and around the world. Bill and his partners invest in promising emerging technology […] Read more
	Charlie Hanna Marcy Venture Partners

	Charlie Hanna is an investor at Marcy Venture Partners (MVP) in San Francisco, an early-stage venture capital firm co-founded by Larry Marcus, Jay Brown and Jay-Z. Charlie’s focus is consumer products and services with an emphasis on sustainability, accessibility and culture. Prior to MVP, Charlie was an Associate at SWAT Equity Partners, a NYC-based venture […] Read more
	SC Moatti Mighty Capital

	SC Moatti is the managing partner of Mighty Capital, a Silicon Valley venture capital firm, and Products That Count, one of the largest communities of product managers, leaders and entrepreneurs in the world. Previously, she built products that billions of people use at Facebook, Nokia and Electronic Arts. She also serves on boards of both […] Read more
	Mario Ruiz Paypal Ventures

	Mario Ruiz is a financial technology investor at PayPal Ventures, focusing on investments in the U.S. and internationally. Prior to joining PayPal, Mario was an investor at Napier Park, where he was a member of a nine-person investment team responsible for the evaluation, diligence, and execution of growth equity and real asset investments. Mario started […] Read more
	Danny Cotter The Westly Group

	Danny Cotter serves as Principal at The Westly Group. Prior to joining the Westly Group, He worked at Pacific Gas & Electric Company where he focused on discovering advanced technology pilots and analyzing regulatory, competitive and technology landscapes to shape smart grid strategies across the organization. While at PG&E, He also helped lead the development […] Read more

UPDATED on 2/26/2020

The dedicated discount code LPBI-VIP and unique event site link http://bit.ly/2PfsbM7 now entitles LPBI network to $350 off the current rates. Applicants should register as soon as possible to lock in the lowest possible rates.

Updated list of over 130 VCs and Angels confirmed to speak and judge.

Partial Lineup of over 130 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Andrew Abrams, Vice President, New Science Ventures | Susan Akbarpour, Partner, Candou Ventures | Joel Albarella, Founder, New York Life Ventures | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Shaun Arora, Founding Partner, MiLA Capital | Doug Atkin, Managing Partner, Communitas Capital Partners | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Mike Biddle, Managing Director, Evok Innovations | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Dave Blivin, Managing Director, Cottonwood Technology Fund | Greg Bohlen, Managing Director, Union Grove Venture Partners | Maureen Boyce, Managing Partner, Good Growth Capital | Peter Bruce-Clark, Partner, Social Impact Capital | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Amy Burr, Managing Director, JetBlue Technology Ventures | Ray Chan, Managing Director, K5 Ventures | Ryan Chou, Investment Associate, JetBlue Technology Ventures | Darren Cooke, Investor, Life Science Angels | Martha Cosgrove, Investing Associate, Boeing HorizonX | Danny Cotter, Principal, The Westly Group | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Ted Driscoll, Managing Partner, DigitalDX Ventures | Robert Dunkle, President, ABES Venture Partners | Ali Farahanchi, Director, DHVC | Anna Fokina, Senior Associate, Data Collective | Isabelle Freidheim, Co-founder & Managing Partner, Starwood VC | Emily Fritze, Senior Associate, The Westly Group | Will Fung, Senior Associate, Samsung Catalyst Fund | Norm Gitis, Managing Partner, Lymo Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Daniel Greene, Principal, Wipro Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Florian Haupt, Partner, TruVenturo | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Michael Julve, Associate, 500 Startups | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Shruti Kothari, Director, Kaiser Permanente Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Marina Levinson, Partner, Benhamou Global Ventures | Larry Li, Managing Partner, AMINO Capital | Darwin Ling, Founding General Partner, Good AI Capital | Catherine Lu, Managing Partner , Alumni Ventures Group (AVG) | Vincent Lui, Partner, XCEL Asia | Hector MacQuarrie, Senior Investment Associate, Shell Ventures | Radhika Malik, Investment Manager, Samsung Catalyst Fund | Ricky Margolis, VP of Business Development, ARIE Capital | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | Eric Meyer, Vice President, Activate Capital | Jonathan Mo, Senior Associate, 11.2 Capital | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Maxim Nazarov, Investor, FinSight Ventures | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Brett Noyes, Founder & Managing Director, Unbank. Ventures | Demi Obayomi, Investor, NextWorld Capital | Nihar Patel, General Partner, Journey Venture Partners | Charles Paul, Vice President – Technology, Henkel Ventures | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Scott Pinizzotto, Senior Investment Director, ENGIE New Ventures | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Jordan Segall, Enterprise Investor, Unusual Ventures | Kristina Serafim, Managing Director, Verizon Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Sean Simpson, Investment Manager, GM Ventures | Ratan Singh, Principal, Fort Ross Ventures | Kenn So, Associate, Shasta Ventures | Allison Steitz, Investor, BlueRun Ventures | Li Sun, Partner, Foundation Capital | Jessica Tan, Associate, 500 Startups | Grahme Taylor, Venture Analyst, Wildcat Venture Partners | Jonathan Tower, Founding Managing Partner, Catapult VC | Erica Van, Investor, Charles River Ventures | Anuj Varma, Investor, BAM Ventures | Kutral Veerabadran, Principal, Flow Capital | Alessandro Vigilante, Head of Global Innovation Ecosystem, Fidelity Investments | Sonali Vijayavargiya, Managing Director, Augment Ventures | Alex Whitney, Senior Analyst, ManchesterStory Group | Henry Wong, Managing Director, Garage Technology Ventures | Joanne Wong, General Partner, REDDS Capital | Russell Yue, Investor, H.I.G. Growth Partners | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more…

UPDATED on 2/6/2020

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to spons and invite you to join us at Venture Summit | West

Special offer: Register Now & Save $450 off (Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23^rd & 24^th 2020

Santa Clara Convention Center, Silicon Valley

Reminder to register for the prestigious Venture Summit | West being held on March 23^rd & 24^th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track. Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies.

Whether you’re a Lifesciences/Healthcare startup seeking capital and exposure, or an investor seeking new deals, Venture Summit West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

Partial Initial Lineup of over 90 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Andrew Abrams, Vice President, New Science Ventures | Susan Akbarpour, Partner, Candou Ventures | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Shaun Arora, Founding Partner, MiLA Capital | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Dave Blivin, Managing Director, Cottonwood Technology Fund | Greg Bohlen, Managing Director, Union Grove Venture Partners | Maureen Boyce, Managing Partner, Good Growth Capital | Peter Bruce-Clark, Partner, Social Impact Capital | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Darren Cooke, Investor, Life Science Angels | Martha Cosgrove, Investing Associate, Boeing HorizonX | Danny Cotter, Principal, Westly Group | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Robert Dunkle, President, ABES Venture Partners | Ali Farahanchi, Director, DHVC | Anna Fokina, Senior Associate, Data Collective | Norm Gitis, Managing Partner, Lymo Ventures | Daniel Greene, Principal, Wipro Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Florian Haupt, Partner, TruVenturo | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Shruti Kothari, Director, Kaiser Permanente Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Marina Levinson, Partner, Benhamou Global Ventures | Larry Li, Managing Partner, AMINO Capital | Darwin Ling, Founding General Partner, Good AI Capital | Catherine Lu, Managing Partner , Alumni Ventures Group (AVG) | Vincent Lui, Partner, XCEL Asia | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | Eric Meyer, Vice President, Activate Capital | Jonathan Mo, Senior Associate, 11.2 Capital | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Brett Noyes, Founder & Managing Director, Unbank.Ventures | Charles Paul, Vice President – Technology, Henkel Ventures | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Scott Pinizzotto, Senior Investment Director, ENGIE New Ventures | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Kristina Serafim, Managing Director, Verizon Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Principal, Fort Ross Ventures | Allison Steitz, Investor, BlueRun Ventures | Li Sun, Partner, Foundation Capital | Grahme Taylor, Venture Analyst, Wildcat Venture Partners | Jonathan Tower, Founding Managing Partner, Catapult VC | Erica Van, Investor, Charles River Ventures | Anuj Varma, Investor, BAM Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Alex Whitney, Senior Analyst, ManchesterStory Group | Henry Wong, Managing Director, Garage Technology Ventures | Russell Yue, Investor, H.I.G. Growth Partners | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more.

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

Register Today & Save Click here. (Use promo code “ LPBI-VIP”)

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

Volunteer Opportunities:

Students and recent alumni are to volunteer to help out for part of the day and enjoy the summit for the other part. Volunteers assist with setup, registration, program coordination, company presentations etc. To join us as a volunteer, please fill out the form here: Click Here http://bit.ly/VSW20VOLUNTEER .

UPDATED on 1/16/2020

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to sponsor and invite you to join us at Venture Summit | West

Special offer: Register Now & Save $450 off (Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23^rd & 24^th 2020

Santa Clara Convention Center, Silicon Valley

Partial Initial Lineup of over 60 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Shaun Arora, Founding Partner, MiLA Capital | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Greg Bohlen, Managing Director, Union Grove Venture Partners | Peter Bruce-Clark, Partner, Social Impact Capital | Darren Cooke, Investor, Life Science Angels | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Jun Deng, Partner, Joyance Partners | Robert Dunkle, President, ABES Venture Partners | Anna Fokina, Senior Associate, Data Collective | Norm Gitis, Managing Partner, Lymo Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Darwin Ling, Founding General Partner, Good AI Capital | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Principal, Fort Ross Ventures | Li Sun, Partner, Foundation Capital | Erica Van, Investor, Charles River Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more.

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

Register Today & Save Click here. (Use promo code “ LPBI-VIP”)

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

We look forward to seeing you there.

LPBI & youngStartup Ventures

@@@@@@

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to announce its sponsorship and invite you to join us at Venture Summit | West

Special offer: Register Now & Save $450 off

(Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23^rd & 24^th 2020

Santa Clara Convention Center, Silicon Valley

Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit | West being held on March 23^rd & 24^th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track.

Lineup of over 150 VCs and Angels that spoke and judged at VSW19 includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Logan Allin, General Partner & Founder, Fin Venture Capital | Kareem Aly, Principal, Thomvest Ventures | Magdi Amin, Investment Partner, Omidyar Network | Ash Archibald, Deal Principal, Wharton Angels | Jennifer Azapian, Partner , Mighty Capital | Carlos S. Baradello, General Partner, Alaya Capital Partners | Scott Beechuk, Partner, Norwest Venture Partners | Marcus Behrendt, Partner, BMW i Ventures | Lisha Bell, Dealflow Lead, Pipeline Angels | Ashish Bhatia, Angel Investor | Sunny Bia, Associate, CRCM Ventures | Mike Biddle, Managing Director, Evok Innovations | Alexa Binns, Associate, Maven Ventures | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Tico Blumenthal, Co-chair of the Medical Device Screening Committee, Life Science Angels | Greg Bohlen, Managing Director, Union Grove Venture Partners | Will Borthwick, Senior Associate, Bold Capital Partners | Eric Breese, Investment Manager, Evonik Venture Capital | Maxx Bricklin, Founding Principal, Bold Capital Partners | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Edouard Bulteau, Investment Manager, Total Energy Ventures | Andy Cao, Principal, Comcast Ventures | Packey Carrier, Investment Manager, American Express Ventures | Jeffrey Carter, General Partner, West Loop Ventures | Matthew Chavez, Associate, New Enterprise Associates | Joy Chen, Chief Investment Officer, TAL Education Group | Kelly Chen, Principal, Data Collective | Keting Chu, Venture Partner, LYFE Capital | Jackson Cummings, Investor, Salesforce Ventures | Michael D’Aurizio, Investment Manager, Centrica Innovations | Ned Daoro, Senior Associate, Clocktower Technology Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Rexhi Dollaku, Principal, Base10 | Yizhen Dong, Principal, 11.2 Capital | Ted Driscoll, Managing Partner, DigitalDX Ventures | Marah Dudenhoeffer, Manager, Verizon Ventures | Susannah Duke, Associate, Pelion Venture Partners | Robert Dunkle, President, ABES Venture Partners | Victor Echevarria, Principal, Jackson Square Ventures | Tom Eggleston, Managing Director , Charmides Capital | Geoffrey Eisenberg, Principal, Ecosystem Integrity Fund | Sean Engel, Principal, Top Tier Capital Partners | Michael Fanfant, Senior Associate, Runa Capital | Chenoa Farnsworth, Managing Director, Blue Startups | Kristen Faulkner, Associate, Threshold Ventures | Linda Fingerle, Partner, Tappan Hill Ventures | Spencer Foust, Principal, Sozo Ventures | Ben Freeberg, Senior Associate, Alpha Venture Partners | Chris Gaertner, Principal, Omega Venture Partners | Karim Gillani, General Partner, Luge Capital | Norm Gitis, Managing Partner, Life Science Angels | Garrett Goldberg, Partner, Bee Partners | Jocelyn Goldfein, Managing Director, Zetta Venture Partners | Daniel Gomez, Investment Analyst, Fusion Fund | Tyler Griffin, Managing Partner, Financial Venture Studio | Baris Guzel, Principal, BMW i Ventures | Perry Ha, Analyst, The Westly Group | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Daniel Harris, Managing Director, DPH Ventures | Laurence Hayward, Partner, Independence Equity | Annie Hazlehurst, Founder, Faridan | Alicia Castillo Holley, Investor, Sand Hill Angels | Jens Horstmann, Founding Director, Crestlight Ventures | Heyu Huang, Venture Partner, Fresco Capital | Anup Jacob, Co-Founder & Managing Director, Activate Capital Partners | Alexis Ji, Partner, Illumina Ventures | Gary Jinks, Founding Managing Director, South Valley Angels | Matt Jones, Managing Director, Solvay Ventures | Kathleen Jurman, Corporate Technology Scout, Dow Ventures | Amir Kabir, Investment Principal, Munich Re Ventures | Jimmy Kan, Senior Associate, Anzu Partners | Kester Keating, Head of US Strategic Investments, Barclays | Roger King, Founder, Bay Angels | Steve Kishi, Managing Director, Hummer Winblad Venture Partners | Yasemin Kliman, Co-President, Harvard Business School Angels | Daniella Kranjac, Co-Founder & Managing Director, Dynamk Capital | Nathan Krishnamurthy, Principal, Capital One Growth Ventures | Vivek Krishnamurthy, Associate, Commerce Ventures | Amit Kumar, Investor, Band of Angels | Kwasi Kyei, Associate, Sandbox Industries | Eduardo Laiter, Sr Investment Analyst, Kapor Capital | Severine Lalande, Investment Manager, Total Energy Ventures | Javaughn Lawrence, Investor, Eniac Ventures | Lindsay Lee, Managing Director, Authentic Ventures | Roberta Lee, Angel Investor, Life Science Angels | Sarah Lee, Investor, EdVentures Group | Julie Lein, Managing Partner, Urban Innovation Fund | Geraldine Le Meur, Founding Partner, The Refiners | Ephraim Lindenbaum, Managing Director, Advance Ventures | Alex Luce, Principal, Creative Ventures | Vincent Lui, Senior Director of Corporate Ventures, SK Telecom Americas | Silvia Mah, Executive Director and Founder, Hera Angels | Ashish Mahashabde, Investor, Amex Ventures | Shripriya Mahesh, Co-Founding Partner, Spero Ventures | Tasneem Manjra, Head of Network Development, Volvo Cars Tech Fund | Jillian Manus, Managing Partner, Structure Capital | Ben Metcalfe, Principal, Ridge Ventures | Wouter Meuleman, Director of Investments, Illumina Ventures | SC Moatti, Managing Partner, Mighty Capital | Linda Molnar, Program Director, National Science Foundation | Sasha Ostojic, Angel investor, Playground Global | Umesh Padval, Venture Partner, Thomvest Ventures | Hirak Parikh, Venture Partner, Augment Ventures | Victor Pascucci III, Managing Partner, Lightbank | Phoebe Peronto, Investor, Salesforce Ventures | Ricardo Politi, Partner, Mindset Ventures | Salil Pradhan, Venture Partner, Draper Nexus | Gagan Rana, Executive-in-Residence, Learn Capital | Peter Redford, Investor, Band of Angels | Bill Reichert, Managing Director, Garage Technology Ventures | John Ricci, Founder & Managing Partner, US Angels | Jennifer Richard, Senior Associate, Cross Culture Ventures | Andre Rocha, Investor, Glasswing Ventures | Riley Rodgers, Associate, Valia Investments | Peter Rojas, Founding Partner, Betaworks Ventures | Praveen Sahay, Managing Director, WAVE Equity Partners | Natalie Sandman, Senior Associate, Shasta Ventures | Miraj Sanghvi, Principal, DigiTx | Jason Schoettler, Co-Founder & Partner, Calibrate Ventures | Wes Selke, Managing Director, Better Ventures | Jayni Shah, Principal, Accomplice | Prashant Shah, Partner, Monta Vista Capita | Ann Shin, Founding Partner, Ultrafund Capital | Charles Sidman, Managing Partner, ECS Capital Partners | Kathleen Siswanto, Investor, Propel Venture Partners | Ira Smith, Director of Venture Investments, Pandect BioVentures | Tanya Soman, Venture Partner, 500 Startups | Shirley Speakman, Partner, Cycle Capital Management | Adam Spector, Angel Investor | Kumar Sripadam, Chair, TiE Global | Jack Statza, Senior Associate, Allstate Strategic Ventures | George Straschnov, Managing Director, Bisk Ventures | Marcus Stroud, Managing Partner, TXV Partners | Mayra Tama, Principal, Initial Capital | Wei Tao, Life Science Angels, Chair Bio Genomics Committee | Craig Taylor, General Partner, Alloy Ventures | Laura Thompson, Principal, Sapphire Ventures | Vishal Verma, General Partner, Edgewood Ventures | Che Voigt, Chairman, North Bay Angels | Jordan Wahbeh, Managing Director, Bay Angels | Timothy Wang, Principal, The Westly Group | Kyoko Watanabe, Managing Director, DEFTA Partners | Patricia Wexler, Co-Founder & Managing Director, Starlight Ventures | James Wu, Senior Associate, M12 | Jonathan Wu, Board Director and Vice President, Sand Hill Angels | Margaret Wu, Investor, Georgian Partners | Veronica Wu, Managing Partner, Hone Capital | Wei Wu, Healthcare Investment Director, BOE Ventures | Matthew Wukasch, Managing Director, Charmides Capital | Wenz Xing, Associate, Bullpen Capital | Sue Xu, Managing Partner , Amino Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Jimmy Zhu, Vice President, Citi Ventures | Shelley Zhuang, Founder and Managing Partner, 11.2 Capital | TX Zhuo, Managing Partner, Fika Ventures and many more.

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

Register Today & Save Click here. (Use promo code “ LPBI-VIP”)

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

We look forward to seeing you there.

LPBI & youngStartup Ventures

LPBI Group – Executive Summary

The Challenge

“Today, there is a digital information explosion in the fields of Life Sciences and Medicine,” said Aviva Lev-Ari, Ph.D., R.N., and founder of Leaders in Pharmaceutical Business Intelligence (LPBI) Group. “To manage that challenge, we are responding to the needs of our multi-faceted audiences in order to guard against information obsolescence through transformational technologies and solutions.”

Our Vision:

LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible.

About LPBI Group

Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, electronic scientific content-creation venture, offering real-time, original scientific content through advanced platform architecture methodologies since 2012. The company’s commitment is to synthesize, analyze and interpret complex, medical and scientific disease information through electronic publishing venues via the cloud to advance the knowledge and research efforts of the scientific and business community.

LPBI Group was created in 2012 by Dr. Aviva Lev-Ari, Ph.D., R.N. The Group has evolved into three, interrelated domains – an open-access online scientific journal, a series of 16 BioMed e-books and real-time press coverage of BioMed scientific and medical conferences. Through this transformative offering, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any subject as well as cutting-edge biomedical research innovation widely available to the scientific and non-research community. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Year over year, there is increased readership of highly valued content, which equates to more than 5,500 scientific articles with over 1.6 million readers in the online scientific journal.

Unique, Experienced Team

The Group employs a team of highly experienced individuals in Life Sciences, particularly within the key domains of BioMedicine, Biotechnology, Pharmaco-therapy, Medical and Information Technology, Health Care and the Life Sciences/Medicine connection.

All members of the LPBI Group team have a wealth of expertise and experience in Life Sciences and have been trained to master the methodology of scientific curation used in the articles. Those individuals include senior MDs, MD/PhDs, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes.

Medical Doctors: Dr. Larry H. Bernstein (retired), Dr. Justin Pearlman (Central Maine Medical Center)
Doctors of Philosophy: Dr. Justin Pearlman, Dr. Stephen Williams, Dr. Sudipta Saha, Dr. Ritu Saxena, Dr. Tilda Barliya, Dr. Irina Robu, Dr. Dror Nir, Dr. Aviva Lev-Ari
Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada), Adam Sonnenberg, PhD(c), Boston University
Executives in Biotechnology and Information Technology Industries: Amnon Danzig, MBA, Europe-Asia (business development consultant with specialization in Strategy, Corporate Finance and Human Capital, published author on Value Creation concepts), Rick Mandahl, MBA, Americas (business development consultant in emerging technologies with Biotech, Information Technology focus), Ritu Saxena (Astellas Pharma), Gail S. Thornton, M.A., PhD(c), (Merck & Co., USA, communications consultant, published author on health, wellness, communications strategy)

Scientific e-Books Source

The 16 BioMed e-books include topics focused on medical science, diagnostics and therapy. The books’ sustainability is maintained by online continuing updates made to articles in the online scientific journal. Each of the scientific e-books contain an abbreviated electronic table of contents, which consists of ‘live’ links from each article in the e-book to the article in the online scientific journal. Readers of the e-books can click on this link to receive the most, updated “State of Science” for each topic. This unique feature makes the e-books relevant and provides a timely source of knowledge and reference.

Highly qualified content consultants, who are senior MDs, MD/PhDs and Professors, are involved in the production and clinical interpretations of the curations. The topics for curation and the contents of the books are uniquely created and carefully edited. Dr. Aviva Lev-Ari as the editor-in-chief leads this multidisciplinary content compilation using her diverse areas of technical training and experience. It should be noted that all of LPBI’s material could, in principle, be translated into other languages.

Journal Ontology

Our intellectual property consists of three classes of Intellectual property assets as described in detail with live links in the following article:

eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/

Three Classes of Intellectual Property Assets

These assets include an open-access online scientific journal with curated, current biomedical research; a series of 16 BioMed e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomic Medicine (a subset of Precision Medicine), Cancer, Immunology and Precision Medicine; and real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in one click operation.

For example, Genomic Medicine, as an emerging medical discipline, is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases and infectious disease. This field involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.

The open-access online scientific journal ontology is a relational and hierarchical knowledge base allowing for expansion of the content creation process between the journal and the series of BioMed e-books, but it is not limited to these two areas. For example, one of the research categories, entitled “Interviews with Scientific Leaders,” includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component used extensively in the BioMed e-Series.

The Group’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. In our seven years together, the Group’s writers and editors generated a remarkable synergy among experts, authors and writers, which yields outstanding collaboration in producing these curations. There are many post-doctoral individuals in the biotechnology industry as well as academia who can serve as experts, authors and writers in continuing the Group’s operations, following appropriate onboarding.

Contact us

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, NJ, Salt Lake City, Berkeley, Cambridge UK, Maine, New Delhi, Palo Alto, Philadelphia, Toronto

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile

Read Full Post »

Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

Posted in BioTechnology - Venture Creation, Innovations, Intellectual Property, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough on July 22, 2019| Leave a Comment »

Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

Reporter: Aviva Lev-Ari, PhD, RN, Berkeley PhD’83

for @Berkeley Alumna Ecosystem Evangelist see

https://pharmaceuticalintelligence.com/2019-vista/executive-summary/

The University of California at Berkeley appointed professor Richard Lyons as the university’s first-ever chief innovation and entrepreneurship officer (CIEO).

The Selection Process

Professor Richard Lyons was selected for the CIEO position through a rigorous recruitment and selection process that attracted several hundred top-notch applications from all over the world. Throughout the process, Lyons stood out as a true visionary, a strategic leader and an ecosystem evangelist who could understand and activate the untapped potential of Berkeley’s innovation and entrepreneurship landscape.

“If together we can improve the transformation of Berkeley’s prodigious intellectual product, across the whole campus, into greater societal benefit, then we will have achieved a great deal,” said Lyons, in a statement.

Image Source: Courtesy of University of California, Berkeley, Doe Library Building with the Campanile Tower in the background

Professor Richard Lyons, Accomplishments as Berkeley’s ex-Dean of the Haas School of Business

He helped launch the Management, Entrepreneurship, & Technology (M.E.T.) dual-degree program in partnership with the College of Engineering.
He also initiated the Biology + Business dual degree program with Molecular & Cell Biology and
He revitalized the Berkeley-Haas Entrepreneurship Program (BHEP).
He helped the campus to launch the Berkeley SkyDeck startup accelerator in 2012 and served on its Governing Board, did that in collaboration with leadership in the Office of Research and College of Engineering.

SOURCE

https://venturebeat-com.cdn.ampproject.org/c/s/venturebeat.com/2019/07/10/richard-lyons-will-be-uc-berkeleys-first-ever-chief-innovation-and-entrepreneurship-officer/amp/

Read Full Post »

Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery

Posted in BioTechnology - Venture Creation, CRISPR/Cas9 & Gene Editing on June 13, 2019| 1 Comment »

Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery

Reporter: Aviva Lev-Ari, PhD, RN

GlaxoSmithKline, UC’s Doudna Establish $67M Genomics, CRISPR Research Lab

Jun 13, 2019 | staff reporter

Save for later

NEW YORK (GenomeWeb) – Drug company GlaxoSmithKline announced today that it will establish a laboratory for CRISPR technologies as part of a five-year collaboration with University of California researchers.

The new Laboratory for Genomics Research (LGR) will investigate disease-causing gene mutations and develop new technologies using CRISPR to accelerate the discovery of new drugs, with a focus on immunology, oncology, and neuroscience. The LGR will receive up to $67 million in funding over the five-year collaboration period, including facilities for 24 full-time university employees funded by GSK, plus up to 14 full-time GSK employees, the company said. GSK’s artificial intelligence and machine learning group will also aid in building any necessary bioinformatics pipelines. The laboratory will be based near the University of California, San Francisco’s Mission Bay campus.

The LGR aims to automate existing CRISPR approaches so that this work can be done at scale. Ultimately, the lab’s goal is to deepen researchers’ understanding of genetics and discover new drug targets. They’re also aiming to create next-generation technologies for the pharmaceutical industry, GSK added.

The LGR will also serve as a resource for investigators at both UCSF and the University of California, Berkeley who can access and use its technology to answer their own research questions and to develop new tools.

The LGR was developed by Berkeley professor and CRISPR expert Jennifer Doudna, UCSF Professor Jonathan Weissman, and GSK CSO and President of R&D Hal Barron.

“Over the last seven years, CRISPR has transformed academic research, but until the LGR, we haven’t had a focused effort to catalyze the kind of research we know will lead to new innovation using this CRISPR tool,” Doudna said in a statement. “LGR is about building that space where creative science is partnered with the development of robust technology that will help develop tomorrow’s drugs. I think we’re going to be able to do science that none of us can even imagine today.”

The collaboration will be governed by a Joint Steering Committee with equitable UC and GSK representation, with additional joint sub-committees covering patents, scientific, and project management, GSK noted. Doudna and Weissman will sit on the committee along with GSK’s new head of functional genomics, Chris Miller.

“One of our key goals is to advance the field overall and make these tools as broadly available as possible,” Weissman added in the statement. “The LGR screening center will enable labs at UCSF and Berkeley, and having access to it will give our scientists opportunities to advance their research in ways that would be very hard for them to do in their own labs.”

ADDITIONAL ARTICLES in GenomeWeb

Jennifer Doudna, GlaxoSmithKline Establish $67M Genomics, CRISPR Research Lab Christie Rizk et al., GenomeWeb, 2019
UC Berkeley, UCSF Use $10M Gift to Launch CRISPR Initiative, Center GenomeWeb, 2014

Big Pharma’s Academic Courtship Continues With Pfizer-UCSF, Glaxo-IDI Research Pacts GenomeWeb, 2008
CSHL Genome Engineering Meeting Shows Maturing CRISPR Technologies GenomeWeb, 2016

SOURCE

https://www.genomeweb.com/business-news/glaxosmithkline-ucs-doudna-establish-67m-genomics-crispr-research-lab#.XQKQ8tNKgcg

Real Time Coverage @BIOConvention #BIO2019: Falling in Love with Science: Championing Science for Everyone, Everywhere

Posted in Conference Coverage with Social Media, Foundations for supporting Science and Education, Open Access Journals, Philanthropy to Academic Institution, Scientific & Biotech Conferences: Press Coverage, Scientific Publishing, Scientist: Career considerations, Women in Life Sciences, tagged #science2_0, science policy, science reporting, Scientific Publishing, women in computing, women in science, Young scientists on June 4, 2019| Leave a Comment »

Falling in Love with Science: Championing Science for Everyone, Everywhere June 4 2019

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Science and technology bring tremendous value to society in years of life and quality of life, yet the public often perceives science as difficult, irrelevant or even threatening. Moreover, the inspirational and moving stories of scientists and innovators working around the world are often hidden or misrepresented in popular culture. Whose responsibility is it to communicate science and engage the public in supporting the scientific enterprise? Can everyone be a Champion of Science and what are the solutions to enlist and engage more champions of science across generations and geographies? How do we work together to enhance transparency, accessibility and relevance of science for everyone, everywhere? Can science become more inclusive and engage hearts and not only minds?

Join this exciting session as Johnson & Johnson announces the winners of the Champions of Science – BioGENEius Storytelling Challenge, and brings together other key stakeholders in a discussion about the importance of engaging the public to fall in love in science all over again.

Sponsored by: Johnson & Johnson Innovation

Speakers

SEEMA KUMARVice President, Innovation, Global Health and Policy Communication atJohnson & Johnson Innovation

Nsikan AkpanDigital Science Producer, PBS News Hour atPBS Newshour

Arthur HorwichSterling Professor of Genetics and Professor of Pediatrics; Investigator HHMI atYale University

Siddhartha MukherjeeAssociate Professor, Medicine atColumbia University

Dr. Maria Luisa PinedaCEO & Co-Founder atEnvisagenics, Inc.

Emily WangSoftware Engineer, Facebook at2014 BioGENEius Challenge Winner

Seema: We need to solve the problem of the lack of trust in scientists. Some of JNJ winners of their acheivement program went on to become Nobel Laureates. Arthur Horwich and Hans Ullrich won the Jannsen Award for discovering compounds that could refold proteins, including protein chaperones. Many diseases occur because of protein misfolding like neuro-degenerative diseases.

Seema: Great science going on in Africa. JNJ wanted to showcase the great science in Africa. they awarded four individuals with storytelling award (Emily).

Dr. Horwich: got interested in science early on. Worked on N terminal mitochondrial signal peptides. also then got interested in how proteins fold and unfold and refold since the 1950s. He had changed the thinking of how proteins are processed within cells and over many years he had worked on this.

Emily Wang: Parents and schoolteachers prodded her curiosity in biology. The impact of day to day work of scientists is arduous but the little things can lead to advances that may help people. If passionate and have a great mentor then can get a foot in the door. Worked at Stanford in the lab.

Dr. Mukherjee: He likes to cure diseases, physican first, scientist second, writer third but he doesn’t separate this. In older times scientists wrote to think and true today. How we visualize the word, or use our hands, is similar. He takes the word translational research very seriously. Can you say in one sentence how this will help patients in three years?

There are multitude ways of love for science.

Dr. Pinela: loved asking big question and loved storytelling but asking bigger questions. Moved from Columbia and moved to US; loved the freedom and government funding situation at that time. Need the training and mentorship so mentors are a very big aspect in innovation as it led her to entrepreneurship. We need to use technology to disrupt and innovate.

Nsikin: A lot of mentors nurture curiosity. People like to see them in that story of curiosity. That is how is bases the PBS science videos: did a study on engagement and people wants a morality, and a science identity (an inner nerd in all of us i.e. spark the interest). The feedback if they focus on this has been positive.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

#itstartswithone

#RightMixMatters

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Foundations for supporting Science and Education, Pharmaceutical Drug Discovery, Scientific & Biotech Conferences: Press Coverage, Venture Capital, tagged #biotech, academic partnership, bioinvestment, Biotech Investment and Venture Growth: The Franchising of Intellectual Property as a Business Model, Global Partnering & Biotech Investment, Public–private partnership, Translational Research on June 4, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Reporter: Stephen J Williams PhD @StephenJWillia2

There is $200B in Global Investment in the Biopharmaceutical Sector Each Year. Who’s Getting It and Why?

115A, Level 100

Speakers

Meir Pugatch Managing Director & Professor atPugatch Consilium; University of Maastricht

Dr. Woei-Jer ChuangDirector General, Department of Life Sciences atMinistry of Science and Technology, Taiwan

Ancizar Guerrero GilForeign Investment Executive Director in the United States atProcolombia

Park Jee MinDeputy Director of the Division of Health Industry Promotion atMinistry of Health and Welfare (MoHW)

Michael PergineAssociate Vice President, International Policy and Government Affairs atMerck & Co.

Prof. Peter PittsPresident and Co-Founder atCenter for Medicine in the Public Interest

Each country have their own needs and most important drug cost structure. Must involve patients and providers.

BCI survey: countries output different, who improved who didnt

Is industry having collaboration with government? hardly ten percent by survey and worse vice versa

Transparancy and holistic view important for collaboration

Korea: lack of communication need input from government on pricing; wants global open innovation and enhance RD investments

Tawain: price, price but based on efficacy; pharma needs to talk with doctors hospital patients, find balance

Pitts: we need trust; staff that country offices with people who know that country. Price not defining value

Columbia: need to attract investors

Navigating Translation: Leveraging Public Private Partnerships to Turn Academic Discoveries into Health

112AB, Level 100

Speakers

Dr. Kathleen RouscheProgram Director at National Institutes of Health/National Heart Lung and Blood Institute

Joseph PiconeProfessor, Department of Electrical and Computer Engineering at Temple University

Dr. Suguna RachakondaSenior Director, Product Development Global Cardiovascular Innovation Center and NCAI-CC at Cleveland Clinic

Dr. Jesus Soriano MollaProgram Director at National Science Foundation

Chris VlahosGlobal Head, Rare Disease External Innovation at Ipsen

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

#itstartswithone

#RightMixMatters

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Delivery Platform Technology, Monoclonal Immunotherapy, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, tagged #biotech, advances in drug development, bioinvestment, Biotech Investment and Venture Growth: The Franchising of Intellectual Property as a Business Model, pharma innovation on June 3, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Speakers

Barbara DaltonVice President, Worldwide Business Development atPfizer Inc.

responsible for VC at Pfizer

Dr. David DonabedianCo-founder, CEO and Director at Axial Biotherapeutics

developing therapeutics based on GI microbiome to treat CNS

Chris GarabedianChairman and CEO atXontogeny, LLC

Xontogeny is an incubator

Curt HerbertsChief Financial Officer and Chief Business Officer atSenti Biosciences, Inc.

David ThomasVice President, Industry Research at Biotechnology Innovation Organization

Ben ThornerSenior Vice President & Head, MRL Business Development & Licensing atMerck & Co., Inc.

Focusing on building their tech platforms

Sam UlinManaging Director atClearView Healthcare Partners

Results from Clarivate

In 2018 most of deals were in CART area but now we are seeing more series A rounds that are on novel mechanisms as well as rare diseases. US is still highest in venture capital series A but next is China. 10 of top ex US VC are from China, a whole lot of money.

Preclinical is very strong for US VC but China VC is focused on clinical. First time this year we see US series A break above 100. But ex US the series A is going down. Although preclinical deals in US is coming back not like as good as in 2006. But alot of > 1 billion $ deals. Most of money into mAbs and protein therapy; antisense is big and cell therapy is big too; small molecule not as much

ClearView Healthcare

Which innovation classes attracted VC in 2018?

Oncology drives a disproportionate focus could be driven by pharma focus on oncology; however there is some focus on neuro and infectious disease
therapeutic classes: shift to differentiated technology…. companies want technologic platforms not just drugs. Nucleic Acid tech and antibody tech is high need platforms. Startups can win by developing a strong platform not just a drug

There are pros and cons of developing a platform company versus a focused company. Many VCs have a portfolio and want something to fit in so look for a focused company and may not want a platform company. Pfizer feels that when alot of money is available (like now) platform investing is fine but when money becomes limited they will focus on those are what will be needed to fill therapy gaps. They believe buy the therapy and only rent the platform.

Merck does feel the way Pfizer does but they have separate ventures so they can look and license platforms. they are active in looking at companies with new modalities but they are focused on the money so they feel best kept in hands of biotech not pharma.

At Celgene they were solely focused on approvals not platforms. Alot of money is required to get these platforms to market. Concentration for platform companies should be the VCs not partnering or getting bought out by pharma. it seems from panel speakers from pharma that they are waiting for science to prove itself and waiting for favorable monetary environments (easy money). However it seems they (big pharma) are indicating that money is drying up or at least expect it too.

At Axial and with VCs they feel it is important to paint a picture or a vision at the early stage.

At Ontogeny, they focus on evaluating assets especially and most important, ThE MANAGEMENT TEAM. There are not that many great talented drug development management teams he feels out there even though great science out there.

Read Full Post »

Older Posts »

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Archive for the ‘BioTechnology – Venture Creation’ Category

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

FE International Framework

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

Professor Richard Lyons, Accomplishments as Berkeley’s ex-Dean of the Haas School of Business

Other related articles published in this Open Access Online Scientific Journal include the following 156 articles:

Follow Blog via Email

Recent Posts

Archives

Categories

Meta

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Archive for the ‘BioTechnology – Venture Creation’ Category

2020 World Medical Innovation Forum – COVID-19, AI – Life Science and Digital Health Investments, MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

FE International Framework

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

2020 State of Possible Conference, MassBio’s Annual Meeting, March 25-26, 2020, Sonesta Hotel, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in REAL TIME

for

by @pharma_BI and by @AVIVA1950

Session Title

Start Time

End Time

3/25/2020 10:00 AM

3/25/2020 10:30 AM

Billy Starr, Founder & Executive Director, Pan Mass Challenge, “Closer by the Mile: How One Man Shaped the Athletic Fundraising Industry with the Power of a Bike”

3/25/2020 10:30 AM

3/25/2020 11:15 AM

3/25/2020 11:15 AM

3/25/2020 12:00 PM

3/25/2020 12:00 PM

3/25/2020 1:00 PM

3/25/2020 1:00 PM

3/25/2020 1:15 PM

3/25/2020 1:15 PM

3/25/2020 2:00 PM

3/25/2020 2:00 PM

3/25/2020 2:15 PM

3/25/2020 2:15 PM

3/25/2020 3:00 PM

3/25/2020 3:00 PM

3/25/2020 3:15 PM

3/25/2020 3:15 PM

3/25/2020 3:30 PM

3/25/2020 3:30 PM

3/25/2020 4:15 PM

3/25/2020 3:30 PM

3/25/2020 4:15 PM

3/25/2020 4:15 PM

3/25/2020 5:00 PM

3/25/2020 4:15 PM

3/25/2020 5:00 PM

3/25/2020 5:00 PM

3/25/2020 5:45 PM

3/25/2020 5:00 PM

3/25/2020 5:45 PM

3/25/2020 6:00 PM

3/25/2020 9:00 PM

3/26/2020 8:45 AM

3/26/2020 9:30 AM

3/26/2020 9:30 AM

3/26/2020 9:45 AM

3/26/2020 9:45 AM

3/26/2020 10:30 AM

3/26/2020 10:30 AM

3/26/2020 10:45 AM

3/26/2020 11:00 AM

3/26/2020 11:45 AM

3/26/2020 11:00 AM

3/26/2020 11:45 AM

3/26/2020 11:45 AM

3/26/2020 12:30 PM

3/26/2020 11:45 AM

3/26/2020 12:30 PM

MassBio’s Innovative Leadership Award honors Dr. Abbie Celniker who has contributed significantly to the growth and success of the life sciences in Massachusetts, is a leader in her communities, and a leader for employees by creating a positive work environment.

3/26/2020 12:30 PM

3/26/2020 1:30 PM

3/26/2020 1:30 PM

3/26/2020 2:30 PM

3/26/2020 2:30 PM

3/26/2020 3:00 PM

SPEAKERS

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is pleased to invite you to youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

@@@@@

Save 20% with discount code LPBI-VIP

UPDATED on 4/21/2020

@@@@

March 23^rd & 24^th 2020